IOVANCE BIOTHERAPEUTICS, INC. reports preliminary estimates of $346.3 million in cash, cash equivalents, investments, and restricted cash as of December 31, 2023, and announces FDA accelerated approval for AMTAGVI (lifileucel) for the treatment of advanced melanoma.